Home / Market News / $ABT

$ABT news and market catalysts

The 38 most recent market catalysts affecting $ABT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

38 catalysts 9 high impact 27 bullish 4 bearish Healthcare
Nov 17, 2026 Corporate Catalyst Bearish Impact 55
Class Action Lawsuit Filed Against Abbott Laboratories Over Glucerna Labeling
Abbott Laboratories is being sued in a class action lawsuit alleging that its Glucerna '1g Total Sugars' shakes are falsely labeled because they contain allulose, which plaintiffs …
Nov 12, 2026 Corporate Catalyst Neutral Impact 65
Abenójar Tungsten, S.A. Provides Post-IPO Operational Update
Abenójar Tungsten, S.A. released its initial post-IPO operational update, highlighting progress at its El Moto tungsten and gold project, with the main decline reaching 60 meters a…
Nov 11, 2026 Corporate Catalyst Bullish Impact 65
Abbott Receives FDA Approval and CE Mark for New Implantable Cardioverter-Defibrillator Lead
Abbott announced it received both U.S. FDA approval and the CE Mark for a new implantable cardioverter-defibrillator (ICD) lead. This is a positive development as it expands Abbott…
Nov 10, 2026 Corporate Catalyst Bullish Impact 55
BofA Analyst Raises Abbott Price Target to $125
Bank of America analyst Travis Steed raised the price target for Abbott Laboratories (ABT) to $125 from a previous undisclosed level, while maintaining a 'Buy' rating. This action …
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Health Canada Approves Expanded Compatibility for mylife Loop with Abbott's FreeStyle Libre 3 Plus Sensor
Health Canada's approval for the mylife Loop system to integrate with Abbott's FreeStyle Libre 3 Plus CGM sensor is a positive development for Abbott. This regulatory milestone exp…
Nov 5, 2026 Corporate Catalyst Bullish Impact 65
Abbott and Novo Nordisk Expand Partnership to Launch Plosbrio® in Asia Pacific
Abbott and Novo Nordisk have announced a strategic partnership to introduce Plosbrio (semaglutide) in the Asia Pacific region. This collaboration is significant as it combines Novo…
Nov 2, 2026 Corporate Catalyst Bullish Impact 65
Abbott Announces Positive One-Year Data for Amulet 360™ Device
Abbott disclosed positive one-year clinical data for its Amulet 360™ device, a significant product in its cardiovascular portfolio. This data, demonstrating high closure rates and …
Nov 2, 2026 Corporate Catalyst Bullish Impact 75
Abbott Announces Positive 30-Day Results from TECTONIC Clinical Trial for SonicForce™ Coronary IVL System
Abbott announced that its TECTONIC clinical trial for the SonicForce™ Coronary IVL System met its primary safety and effectiveness endpoints, with a very low 0.3% target lesion fai…
Oct 29, 2026 Corporate Catalyst Bullish Impact 60
Abbott Initiates Pivotal Trial for Cephea™ Mitral Heart Valve Device
Abbott has initiated a pivotal clinical trial for its Cephea mitral heart valve device, a crucial step in bringing new medical technology to market. This development is significant…
Oct 27, 2026 Corporate Catalyst Bullish Impact 55
Abbott's Role in the Growing Global Leadless Pacemaker Market
Abbott's 8-K filing outlines its significant role in the leadless pacemaker market, specifically with its AVEIR DR system, which addresses a critical need for dual-chamber pacing. …
Oct 23, 2026 Corporate Catalyst Bullish Impact 65
Abbott Presents New Data on Oncodetect® Whole-Genome Sequencing Test for Colorectal Cancer
Abbott presented new clinical data at ESMO for its Oncodetect® whole-genome sequencing test, indicating a 30% absolute improvement in sensitivity for colorectal cancer detection. T…
Oct 21, 2026 Corporate Catalyst Bearish Impact 85
Abbott Laboratories shares are trading lower after the company reported Q3 financial results and narrowed its FY26 adjusted EPS guidance. The company announced it will spin off its nutrition business into an independent publicly traded company.
The headline presents a significant corporate catalyst for Abbott Laboratories (ABT). The immediate negative reaction is driven by the narrowed FY26 EPS guidance, suggesting a less…
Oct 21, 2026 Corporate Catalyst Neutral Impact 75
Abbott Laboratories Sees Q4 Adj EPS $1.62-$1.67 vs $1.64 Est
Abbott Laboratories (ABT) has released its Q4 adjusted EPS guidance, forecasting a range of $1.62 to $1.67. This guidance is significant because it directly compares to the analyst…
Oct 21, 2026 Corporate Catalyst Bullish Impact 65
Abbott Laboratories Q3 Adj. EPS $1.42, Inline, Sales $13.013B Beat $12.998B Estimate
Abbott Laboratories announced its Q3 earnings, reporting adjusted EPS of $1.42, which was in line with analyst consensus. Sales came in at $13.013 billion, slightly beating the $12…
Oct 21, 2026 Corporate Catalyst Bullish Impact 92
Abbott To Spin Off Nutrition Business Into Independent Public Company With $8.5B In Annual Sales; Separation Expected To Be Completed By 2027 End
Abbott is spinning off its Nutrition business, which generates $8.5 billion in annual sales, into a new independent public company. This move is significant because it allows both …
Oct 19, 2026 Corporate Catalyst Neutral Impact 75
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings
The filing highlights that Abbott Laboratories (ABT) is set to release its Q3 earnings, with analysts forecasting growth in both EPS and revenue compared to the prior year. Several…
Oct 7, 2026 Corporate Catalyst Neutral Impact 55
Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $120
Barclays analyst Matt Miksic initiated coverage on Abbott Laboratories (ABT) with an 'Overweight' rating and a $120 price target. This event is significant as new analyst coverage,…
Oct 5, 2026 Corporate Catalyst Bullish Impact 75
Abbott shares are trading higher after the company received FDA approval for CardioMEMS HF System updates that add new patient-facing features through the CardioGuide HF App.
This FDA approval is a significant positive for Abbott (ABT) as it enhances the functionality and patient engagement of its CardioMEMS HF System, a key product in its cardiovascula…
Oct 5, 2026 Corporate Catalyst Bullish Impact 55
FDA Approves Abbott's Updated CardioMEMS HF System
Abbott announced FDA approval for updates to its CardioMEMS HF System, specifically enabling a new CardioGuide HF App for patients. This app allows U.S. CardioMEMS patients to view…
Oct 2, 2026 Corporate Catalyst Bullish Impact 65
Rothschild & Co Upgrades Abbott Laboratories to Buy, Raises Price Target to $127
Rothschild & Co analyst Ed Ridley-Day upgraded Abbott Laboratories (ABT) from Neutral to Buy and raised the price target from $119 to $127. This upgrade signals a more optimistic v…
Sep 22, 2026 Market Technicals Neutral Impact 55
3 Health Care Stocks With Whale Alerts In Today’s Session
The filing details 'whale alerts' in options trading for ABT, SMMT, and NVO, indicating significant institutional or large-scale investor activity. For ABT, a bullish put sweep sug…
Aug 20, 2026 Corporate Catalyst Bullish Impact 75
Abbott Reaches ~$670M Settlement With Three Law Firms To Resolve Gill Case Involving ~2K Individuals Regarding Special Formulas For Pattern Infants
Abbott has reached a settlement totaling approximately $670 million to resolve the Gill case, which initially resulted in a $495 million verdict against the company, and claims fro…
Aug 13, 2026 Corporate Catalyst Bullish Impact 65
Wolfe Research Upgrades Abbott Laboratories to Outperform, Announces $130 Price Target
Wolfe Research analyst Mike Polark upgraded Abbott Laboratories (ABT) from 'Peer Perform' to 'Outperform' and announced a new price target of $130. This upgrade indicates a more bu…
Aug 11, 2026 Corporate Catalyst Neutral Impact 65
Abbott Partners With Google Health To Combine Glucose Insights From Abbott's Lingo Biowearable With Google's Expertise In AI To Make Personalized Metabolic Insights More Actionable
Abbott is collaborating with Google Health to combine glucose insights from its Lingo biowearable with Google's AI expertise. This partnership aims to deliver personalized, actiona…
Jul 17, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120
JP Morgan analyst Robbie Marcus has maintained an 'Overweight' rating on Abbott Laboratories and raised the price target from $110 to $120. This action signals continued confidence…
Jul 17, 2026 Corporate Catalyst Bullish Impact 65
Abbott Laboratories shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $131 to $134. Also, Evercore ISI Group maintained its Outperform rating and raised its price target from $112 to $120.
This headline indicates a positive corporate catalyst for Abbott Laboratories. The maintained 'Buy' and 'Outperform' ratings, coupled with increased price targets from BTIG and Eve…
Jul 17, 2026 Corporate Catalyst Bullish Impact 85
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results
Abbott Laboratories delivered a strong second quarter, surpassing analyst expectations for both adjusted earnings and revenue. The company's decision to raise its full-year 2026 ad…
Jul 17, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Group Maintains Outperform on Abbott Laboratories, Raises Price Target to $120
Evercore ISI Group's analyst Vijay Kumar has raised the price target for Abbott Laboratories (ABT) from $112 to $120 while maintaining an 'Outperform' rating. This upgrade signals …
Jul 17, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on Abbott Laboratories, Raises Price Target to $134
BTIG analyst Marie Thibault maintained a 'Buy' rating on Abbott Laboratories and raised the price target from $131 to $134. This action signals continued confidence from a prominen…
Jul 16, 2026 Corporate Catalyst Bullish Impact 75
Shares of medical device companies are trading higher amid sympathy with Abbott Laboratories after that company reported better-than-expected Q2 financial results and raised its FY adjusted EPS guidance with its midpoint above estimates.
This headline indicates a significant positive catalyst for the medical device sector. Abbott's strong performance suggests robust demand or effective cost management within the in…
Jul 16, 2026 Corporate Catalyst Bullish Impact 95
Abbott Brushes Off Procedure Volume Concerns, Lifts Outlook
Abbott Laboratories delivered a strong Q2 2026 performance, surpassing Wall Street estimates for both earnings and revenue. This positive financial report is significant as it led …
Jul 16, 2026 Corporate Catalyst Bullish Impact 85
Abbott Laboratories shares are higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance.
This headline represents a significant corporate catalyst for Abbott Laboratories. Better-than-expected earnings and, more importantly, raised long-term guidance (FY26) signal stro…
Jul 16, 2026 Corporate Catalyst Bearish Impact 85
ABT stock has given up its prior loss. Abbott Laboratories shares were trading lower after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance.
This headline highlights a significant corporate catalyst for Abbott Laboratories. The initial dip despite positive news suggests potential profit-taking or an overreaction to some…
Jul 16, 2026 Corporate Catalyst Bearish Impact 85
Abbott Laboratories shares are trading lower after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance.
The primary impact is on Abbott Laboratories (ABT), which is experiencing a negative price reaction despite seemingly positive corporate news. This 'sell the news' phenomenon often…
Jul 16, 2026 Corporate Catalyst Bullish Impact 95
Abbott Stock's Best Day Ever: +13.6% On Earnings Beat, Guidance Raise
Abbott Laboratories experienced its best single-day stock performance since 1968, jumping 13.6% after reporting Q2 adjusted earnings of $1.31 per share (vs. $1.28 consensus) and sa…
Jul 16, 2026 Corporate Catalyst Bullish Impact 85
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday
The filing highlights several companies experiencing significant positive stock movements on Thursday. Abbott Laboratories, ManpowerGroup, and UnitedHealth Group all reported stron…
Jul 16, 2026 Corporate Catalyst Bullish Impact 75
Abbott Projects Full-Year 2026 Comparable Sales Growth Of 6.5% To 7.5%
Abbott's projection of 6.5% to 7.5% comparable sales growth for full-year 2026 is a significant positive indicator for the company. This long-term outlook suggests strong underlyin…
Jul 16, 2026 Corporate Catalyst Neutral Impact 75
Abbott Laboratories Sees Q3 Adj EPS $1.38-$1.46 vs $1.42 Est
Abbott Laboratories (ABT) has released its Q3 adjusted EPS guidance, projecting a range of $1.38 to $1.46. This guidance is significant because it provides investors with an update…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.